Sanofi reported first-half 2026 revenue of EUR 22.1 billion (USD 25.8 billion), up 15.7% in constant exchange rates, with R&D at EUR 4.0 billion (18.0% of sales). Dupixent (dupilumab) delivered EUR 9.3 billion (USD 10.9 billion, +34.4%) and surpassed EUR 5 billion in a single quarter, offsetting China vaccine softness (EUR 1.3 billion, -3.5% on birth-rate-driven paediatric vaccine declines). Immunology contributed EUR 9.6 billion, rare disease EUR 3.6 billion (+32.3% for Altuviiio), oncology EUR 490 million, and vaccines EUR 2.4 billion (Beyfortus +13.2%, flu/COVID-19 -42.1%).

Sanofi raised its 2026 sales growth guidance to approximately 10% in constant currencies and upgraded the 2030 Dupixent revenue target from EUR 22 billion to EUR 25 billion, despite mixed dermatology setbacks (chronic prurigo nodularis Phase III misses, European bullous pemphigoid withdrawal).

Sarclisa subcutaneous formulation is rolling out across the US, EU, and Japan, and cenrifki (a BTK inhibitor) was approved in the EU for secondary progressive multiple sclerosis (MS).

The update signals confidence in dupilumab's multi-indication expansion – including paediatric chronic spontaneous urticaria – as the central pillar of Sanofi's immunology-dominated growth model through the decade.